• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服制剂中甾体药物的掩味

Taste Masking of Steroids for Oral Formulations.

作者信息

Ahmed Kawther Khalid, Kassab Hanan Jalal, Al Ramahi Intesar Jawad, Alwan Zahraa Salim

机构信息

University of Baghdad, College of Pharmacy, Department of Pharmaceutics, Baghdad, Iraq.

Avi Sina Center for Pharmaceutical Research, Corporation of Research and Industry Development, Baghdad, Iraq.

出版信息

Turk J Pharm Sci. 2024 Jan 19;20(6):352-360. doi: 10.4274/tjps.galenos.2023.24968.

DOI:10.4274/tjps.galenos.2023.24968
PMID:38254331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10803926/
Abstract

OBJECTIVES

Oral steroids are commonly prescribed to children. Steroids have a strong bitter taste that limits their oral acceptance in children. The objective of this study was to formulate a pediatric-friendly and palatable oral dosage form of steroids.

MATERIALS AND METHODS

Solid dispersions of dexamethasone were prepared using polyethylene glycol, pectin, and Eudragit as carrier polymers, and chocolate as a flavoring agent. Taste masking efficiency was evaluated by healthy volunteers to select the best formula. The selected formula was pressed into chewable tablets with varying amounts of sweeteners. Chewable tablets were evaluated for palatability, hardness, and chewing index. The typical application of the taste masking approach was confirmed using prednisolone.

RESULTS

Eudragit-based solid dispersions were effective in dexamethasone taste masking. Using 40% mannitol resulted in palatable tablets with acceptable hardness and chewing difficulty. The effectiveness of the taste masking approach was successfully used to prepare prednisolone chewable tablets. However, an increase in the carrier: drug ratio and a change in the flavor to pineapple were necessary to achieve maximum palatability of prednisolone chewable tablets.

CONCLUSION

Eudragit solid dispersion is an effective method for the taste masking highly bitter steroids. The solid dispersion was successfully pressed into a palatable, easy-to-chew, and pediatric-friendly chewable tablet dosage form. The carrier: drug ratio and the choice of flavoring agent are crucial factors in improving tablet palatability.

摘要

目的

口服类固醇药物常用于儿童。类固醇具有强烈的苦味,这限制了儿童对其口服的接受度。本研究的目的是研制一种对儿童友好且口感良好的类固醇口服剂型。

材料与方法

以聚乙二醇、果胶和丙烯酸树脂为载体聚合物,巧克力为调味剂,制备地塞米松固体分散体。通过健康志愿者评估掩味效果以选择最佳配方。将所选配方压制成含有不同量甜味剂的咀嚼片。对咀嚼片的口感、硬度和咀嚼指数进行评估。使用泼尼松龙证实了掩味方法的典型应用。

结果

基于丙烯酸树脂的固体分散体对地塞米松有有效的掩味作用。使用40%的甘露醇可得到口感良好、硬度和咀嚼难度可接受的片剂。掩味方法的有效性成功用于制备泼尼松龙咀嚼片。然而,为了使泼尼松龙咀嚼片达到最大的适口性,需要提高载体与药物的比例并将调味剂改为菠萝味。

结论

丙烯酸树脂固体分散体是一种有效掩蔽高苦味类固醇药物的方法。该固体分散体成功压制成口感良好、易于咀嚼且对儿童友好的咀嚼片剂型。载体与药物的比例和调味剂的选择是提高片剂适口性的关键因素。

相似文献

1
Taste Masking of Steroids for Oral Formulations.口服制剂中甾体药物的掩味
Turk J Pharm Sci. 2024 Jan 19;20(6):352-360. doi: 10.4274/tjps.galenos.2023.24968.
2
Development of Child-Friendly Lisdexamfetamine Chewable Tablets Using Ion Exchange Resin as a Taste-Masking Carrier Based on the Concept of Quality by Design (QbD).基于质量源于设计(QbD)理念,使用离子交换树脂作为掩味载体开发儿童友好型利斯的明咀嚼片。
AAPS PharmSciTech. 2023 Jun 8;24(5):132. doi: 10.1208/s12249-023-02592-x.
3
The Development of a Chocolate-Based Chewable Tablet of Prednisolone-Enhancing the Palatability of Steroids for Pediatric Use.一种基于巧克力的泼尼松龙咀嚼片的研发——提高儿科用类固醇药物的适口性
Pharmaceutics. 2024 Aug 21;16(8):1099. doi: 10.3390/pharmaceutics16081099.
4
Novel levocetirizine HCl tablets with enhanced palatability: synergistic effect of combining taste modifiers and effervescence technique.具有增强适口性的新型盐酸左西替利嗪片:味觉改良剂与泡腾技术联合使用的协同效应
Drug Des Devel Ther. 2015 Sep 7;9:5135-46. doi: 10.2147/DDDT.S92245. eCollection 2015.
5
Development of Oral Flexible Tablet (OFT) Formulation for Pediatric and Geriatric Patients: a Novel Age-Appropriate Formulation Platform.用于儿科和老年患者的口服柔性片剂(OFT)制剂的开发:一种新型的适合年龄的制剂平台。
AAPS PharmSciTech. 2017 Aug;18(6):1972-1986. doi: 10.1208/s12249-016-0666-0. Epub 2016 Dec 5.
6
Development of oral acetaminophen chewable tablets with inhibited bitter taste.具有抑制苦味的口服对乙酰氨基酚咀嚼片的研制
Int J Pharm. 2003 Jan 30;251(1-2):123-32. doi: 10.1016/s0378-5173(02)00595-1.
7
Development and evaluation of artemether taste masked rapid disintegrating tablets with improved dissolution using solid dispersion technique.采用固体分散技术开发和评价具有改善溶出度的蒿甲醚掩味速崩片。
AAPS PharmSciTech. 2008;9(2):494-500. doi: 10.1208/s12249-008-9066-4. Epub 2008 Mar 20.
8
In vitro and in vivo investigation of taste-masking effectiveness of Eudragit E PO as drug particle coating agent in orally disintegrating tablets.以丙烯酸树脂E PO为口腔崩解片药物颗粒包衣剂的掩味效果的体外和体内研究。
Drug Dev Ind Pharm. 2017 May;43(5):723-731. doi: 10.1080/03639045.2016.1220572. Epub 2016 Aug 21.
9
Formulation and in vitro evaluation of ketoprofen fast-dissolving tablets.酮洛芬速溶片的处方设计与体外评价
Pharm Dev Technol. 2016 Dec;21(8):901-908. doi: 10.3109/10837450.2015.1022792. Epub 2015 Mar 23.
10
Orodispersible films and tablets with prednisolone microparticles.含泼尼松龙微粒的口腔崩解膜和片剂。
Eur J Pharm Sci. 2015 Jul 30;75:81-90. doi: 10.1016/j.ejps.2015.04.006. Epub 2015 Apr 16.

引用本文的文献

1
Kollicoat Smartseal 100P for Developing Theophylline Pellets: Exploring Taste-Masking Potential for Pediatric Applications.用于开发茶碱微丸的Kollicoat Smartseal 100P:探索儿科应用中的掩味潜力。
Pharmaceutics. 2025 Mar 25;17(4):413. doi: 10.3390/pharmaceutics17040413.
2
Utilization of the Drug-Polymer Solid Dispersion Obtained by Ball Milling as a Taste Masking Method in the Development of Orodispersible Minitablets with Hydrocortisone in Pediatric Doses.在儿科剂量氢化可的松口腔崩解片的研发中,利用球磨法制备的药物-聚合物固体分散体作为一种掩味方法。
Pharmaceutics. 2024 Aug 4;16(8):1041. doi: 10.3390/pharmaceutics16081041.

本文引用的文献

1
Drug-handling problems and expectations of the ideal pediatric drug-reported by children and their parents.儿童及其家长报告的药物处理问题和对理想儿科药物的期望。
Eur J Pediatr. 2022 May;181(5):2161-2171. doi: 10.1007/s00431-022-04419-6. Epub 2022 Feb 23.
2
Paediatric specific dosage forms: Patient and formulation considerations.儿科专用剂型:患者和剂型考虑因素。
Int J Pharm. 2022 Mar 25;616:121501. doi: 10.1016/j.ijpharm.2022.121501. Epub 2022 Jan 29.
3
Development of raft-forming liquid and chewable tablet formulations incorporating quercetin solid dispersions for treatment of gastric ulcers.用于治疗胃溃疡的含槲皮素固体分散体的筏状形成液体制剂和咀嚼片制剂的研发。
Saudi Pharm J. 2021 Oct;29(10):1143-1154. doi: 10.1016/j.jsps.2021.08.005. Epub 2021 Aug 9.
4
Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.药物非晶态固体分散体:制备策略综述
Acta Pharm Sin B. 2021 Aug;11(8):2505-2536. doi: 10.1016/j.apsb.2021.05.014. Epub 2021 Jun 5.
5
Children's Preferences for Oral Dosage Forms and Their Involvement in Formulation Research via EPTRI (European Paediatric Translational Research Infrastructure).儿童对口服剂型的偏好以及他们通过欧洲儿科转化研究基础设施(EPTRI)参与剂型研究的情况。
Pharmaceutics. 2021 May 15;13(5):730. doi: 10.3390/pharmaceutics13050730.
6
Prior administration of chocolate improves the palatability of bitter drugs: The Choc-with-Med study.巧克力预先给药可改善苦味药物的口感:巧克力与药物研究。
J Paediatr Child Health. 2021 Aug;57(8):1267-1273. doi: 10.1111/jpc.15448. Epub 2021 Mar 19.
7
Patent landscape of pediatric-friendly oral dosage forms and administration devices.儿科口服剂型和给药装置的专利全景。
Expert Opin Ther Pat. 2021 Jul;31(7):663-686. doi: 10.1080/13543776.2021.1893691. Epub 2021 Apr 19.
8
Investigation of Pectin-Hydroxypropyl Methylcellulose-Coated Floating Beads for Pulsatile Release of Piroxicam.用于吡罗昔康脉冲释放的果胶-羟丙基甲基纤维素包衣漂浮珠的研究。
Turk J Pharm Sci. 2020 Oct;17(5):542-548. doi: 10.4274/tjps.galenos.2019.99896. Epub 2020 Oct 30.
9
Formulation and Characterization of Solid Dispersions of Etoricoxib Using Natural Polymers.依托考昔用天然聚合物的固体分散体的制剂与表征
Turk J Pharm Sci. 2020 Feb;17(1):7-19. doi: 10.4274/tjps.galenos.2018.04880. Epub 2020 Feb 19.
10
Solid Dosage Forms of Dexamethasone Sodium Phosphate Intended for Pediatric Use: Formulation and Stability Studies.用于儿科的地塞米松磷酸钠固体剂型:制剂与稳定性研究
Pharmaceutics. 2020 Apr 14;12(4):354. doi: 10.3390/pharmaceutics12040354.